Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection.
Community-acquired infections caused by methicillin-resistant Staphylococcus aureus (MRSA) expressing the Panton-Valentine leukocidin (PVL) are rampant, but the contribution of PVL to bacterial virulence remains controversial. While PVL is usually viewed as a cytotoxin, at sublytic amounts it activates protective innate immune responses. A leukotoxic effect might predominate in high inoculum studies, whereas protective proinflammatory properties might predominate in settings with lower bacterial inocula that more closely mimic what initially occurs in humans. However, these protective effects might possibly be neutralized by antibodies to PVL, which are found in normal human sera and at increased levels following PVL(+) S. aureus infections. In a low-inoculum murine skin abscess model including a foreign body at the infection site, strains deleted for the pvl genes replicated more efficiently within abscesses than isogenic PVL(+) strains. Coinfection of mice at separate sites with isogenic PVL(+) and PVL(-) MRSA abrogated the differences in bacterial burdens, indicating a systemic effect on host innate immunity from production of PVL. Mice given antibody to PVL and then infected with seven different PVL(+) strains also had significantly higher bacterial counts in abscesses compared with mice given nonimmune serum. Antibody to PVL had no effect on MRSA strains that did not produce PVL. In vitro, antibody to PVL incapacitated PVL-mediated activation of PMNs, indicating that virulence of PVL(+) MRSA is enhanced by the interference of PVL-activated innate immune responses. Given the high rates of primary and recurring MRSA infections in humans, it appears that antibodies to PVL might contribute to host susceptibility to infection.
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Pauline
P
Yoong
Gerald B
GB
Pier
D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000097:blood*; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000097:blood; D001427:Bacterial Toxins / Q000235:genetics / Q000276:immunology; D015169:Colony Count, Microbial; D017714:Community-Acquired Infections / Q000276:immunology* / Q000382:microbiology*; D005098:Exotoxins / Q000235:genetics / Q000276:immunology; D005798:Genes, Bacterial; D006801:Humans; D007113:Immunity, Innate; D007956:Leukocidins / Q000235:genetics / Q000276:immunology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D051379:Mice; D011817:Rabbits; D013203:Staphylococcal Infections / Q000276:immunology* / Q000382:microbiology*; D013207:Staphylococcal Skin Infections / Q000276:immunology / Q000382:microbiology; D014774:Virulence / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin